References
1. Sobin, L. H.; Gospodarowicz, M. K.; Wittekind, C. H.. TNM
classification of malignant tumors. 7th ed. West Sussex, UK: John Wiley
& Sons; 2009.
2. Tanaka, K. 2020. IV. Treatment of unresectable cases-immune
checkpoint inhibitor. Gan To Kagaku Ryoho Cancer & Chemotherapy
47:1050-54.
3. Kiyota, N., Hasegawa, Y.,
Takahashi, S., Yokota, T., Yen, C.J., Iwae, S., et al. 2017. A
randomized, open-label, Phase â…¢ clinical trial of nivolumab vs. therapy
of investigator’s choice in recurrent squamous cell carcinoma of the
head and neck: A subanalysis of Asian patients versus the global
population in checkmate 141. Oral Oncology 73:138-146.
4. Hanamure, Y., Hayashi, T., Takaki, M., Ito, K. 2019. Response to
salvage chemotherapy after progression on nivolumab in patients with
recurrent/metastatic head and neck squamous cell carcinoma. Japanese
Journal of Head and Neck Cancer 45:41-45.
5. Park, S.E., Lee, S.H., Ahn, J.S., Ahn, M.J., Park, K., Sun, J.M.
2018. Increased response rates to salvage chemotherapy administered
after PD-1/PD-L1 inhibitors in patients with Non-small Cell Lung Cancer.
Journal of Thoracic Oncology 13:106-111.
6. Schvartsman, G., Peng, S.A.,
Bis, G., Lee, J.J., Benveniste, M.F.K., Zhang, J., et al. 2017. Response
rates to single-agent chemotherapy after exposure to immune checkpoint
inhibitors in advanced non-small cell lung cancer. Lung Cancer
112:90-95.
7. Ogawara, D., Soda, H., Iwasaki, K., Suyama, T., Taniguchi, H.,
Fukuda, Y., et al. 2018. Remarkable response of nivolumab-refractory
lung cancer to salvage chemotherapy. Thoracic Cancer 9:175-180.
8. Santini, D., Vincenzi, B., Addeo, R., Garufi, C., Masi, G.,
Scartozzi, M., et al. 2012. Cetuximab rechallenge in metastatic
colorectal cancer patients: how to come away from acquired resistance?
Annals of Oncology 23:2313-2318.
9. Aparicio, S., Caldas, C. 2013. The implications of clonal genome
evolution for cancer medicine. New England Journal of Medicine
368:842-851.
10. Ueda, M., Rin, S., Niiyama,
T., Hata, H., Imamachi, K. 2018. Collaboration in medical treatment to
use Nivorumab against oral cancer, Clinical Oncologist and Oral and
Maxillofacial surgeon. Journal of Japanese Society of Oral Oncology
30:135-143.
11. Jackaman, C., Majewski, D., Fox, S.A., Nowak, A.K., Nelson, D.J.
2012. Chemotherapy broadens the range of tumor antigens seen by
cytotoxic CD8(+) T cells in vivo. Cancer Immunology, Immunotherapy
61:2343-2356.
12. Shurin, G.V., Tourkova, I.L., Kaneno, R., Shurin, M,R. 2009.
Chemotherapeutic agents in noncytotoxic concentrations increase antigen
presentation by dendritic cells via an IL-12-dependent mechanism.
Journal of Immunology 183:137-144.
13. Vincent, J., Mignot, G., Chalmin, F., Ladoire, S., Bruchard, M.,
Chevriaux, A., et al. 2010. 5-Fluorouracil selectively kills
tumor-associated myeloid-derived suppressor cells resulting in enhanced
T cell-dependent antitumor immunity. Cancer Reserach 70:3052-3061.